BRL-50481

• Description:

  BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15, 12.1, 62 and 490 μM for PDE7A, PDE7B, PDE4 and PDE3, respectively.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/BRL-50481.html

• Purity:

  99.81

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=S(C1=CC([N+]([O-])=O)=CC=C1C)(N(C)C)=O

• Molecular Formula:

  C9H12N2O4S

• Molecular Weight:

  244.27

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Safavi M, et al. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurologicaland inflammatory disorders. Expert Opin Drug Discov. 2013 Jun;8 (6) :733-51.|[2]Smith SJ, et al. Discovery of BRL 50481 [3- (N, N-dimethylsulfonamido) -4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol. 2004 Dec;66 (6) :1679-89.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PDE7

• CAS Number:

  [433695-36-4]